Oncology investment & partnering trends
Thursday, May 9th - 10:00 EDT | 15:00 BST | 16:00 CEST

Sign me up

What you need to know about the oncology deals landscape

Pharma investment in oncology is far and above all other therapeutic areas, with dealmaking and partnering a core strategy in that investment. In just the last 4 years, oncology deal values totaled a whopping $331 billion. From the top 20 pharma companies to small start-ups, oncology is pulling investment from across life sciences.

This webinar will dive into pharma’s largest sector to examine:

● The most recent oncology deals activity, including a look at deal types, volume, regulatory designation, and phase

● The most prevalent and emerging technologies

● Competitive landscape for the top 10 oncology licensing deals

● Private and VC investment activity across the oncology landscape

● Best practices for partnering


Who should attend?

  • If you’re a current investor or positioning your asset for partnering,
    this webinar will provide valuable inputs for your next move.


Sarah E. Hardison, Ph.D.
Therapeutic Area Director, Immunology & Immuno-oncology, Clarivate Analytics


Willie Reaves
Director, Partnering Products & Services, Biotechnology Innovation Organization (BIO)

  • PhD in Immunology at the University of Texas
  • Postdoctoral fellowship at the University of Aberdeen, where she focused on the discovery and characterization of novel immune receptors.
  • 18 peer-reviewed publications, appearing in high-impact journals such as Nature, Nature Immunology, and Nature Microbiology



  •  Leads product development for the BIO One-on-One Partnering™ system, a software platform that connects life sciences companies to facilitate partnerships and drug development.
  • Oversees B2B operations for BIO’s portfolio of business development & licensing events across North America, Latin America, Europe, and Asia.